A computer-implemented method for selecting patient cohorts for clinical trials that retrieves candidate medical records from an electronic medical repository and analyzes historical patient data for an initial population of candidate patients eligible for the clinical trial. The method identifies adverse effect patient characteristics associated with severe adverse effects (SAE) or excessive adverse effects (EAE) for a proposed treatment and removes candidate patients having such characteristics. The method further identifies and removes patients having negative outcome patient characteristics associated with treatment failure, while identifying positive outcome patient characteristics associated with treatment success. The method returns a subset of eligible candidate patients based on positive outcome characteristics while excluding those with adverse effect or negative outcome characteristics.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G06N 7/01 - Modèles graphiques probabilistes, p. ex. réseaux probabilistes
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p. ex. leurs effets secondaires ou leur usage prévu
2.
USE OF BAIAP2 INHIBITORS SUCH AS SUBSTITUTED PHENAZINES TO TREAT CANCER
Disclosed are small molecule inhibitors useful in reducing or ameliorating the proliferation and migration of cancer. Pharmaceutical compositions containing the small molecule inhibitors are also disclosed. Additionally, methods of treating diseases or conditions using the small molecule inhibitors are disclosed. The disease, disorder, or condition may be inflammatory conditions, neurological or neurodegenerative conditions, or autoimmune conditions. The diseases or conditions described herein may benefit from the inhibition of BAIAP2 expression using the small molecule inhibitors described herein.
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Systems and methods are provided for assessing creativity and diversity in verbal content. A system receives input text, generates embeddings for ideas in the text, creates a heat map of idea locations in an embedding space, analyzes trajectories of ideas through the embedding space, calculates diversity scores based on idea locations and trajectories, compares individual text diversity to a larger dataset, and generates a report on generative diversity. Novel metrics are introduced, including Idea Cluster Uniqueness (ICU), Diversity Polarity (DP), and Thematic Profile (TP) scores. The system may utilize advanced techniques such as hierarchical clustering, topic modeling, and neural networks to provide comprehensive evaluations of creativity and diversity in written content.
Systems and processes described herein are for monitoring data records and predicting changes to coded values in the data records. More specifically, this disclosure relates to predicting and potentially preventing anomalies represented in data records by predicting values of entries to be added to the data records and causing a prophylactic response to the predicted anomaly to prevent the anomaly from occurring.
Systems and processes described herein are for monitoring data records and predicting changes to coded values in the data records. More specifically, this disclosure relates to predicting and potentially preventing anomalies represented in data records by predicting values of entries to be added to the data records and causing a prophylactic response to the predicted anomaly to prevent the anomaly from occurring.
Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. Also provided are methods for increasing sensitivity of a (CCK) receptor-expressing cancerous tumor in a subject to immunotherapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
7.
SYSTEMS AND METHODS FOR FACILITATING AUTONOMOUS ACTOR ARCHITECTURES
A system for evaluating and enhancing an autonomous actor network includes: a first computer-implemented current state assessment module, assessing a current autonomous actor network representation and providing a first output; a second computer-implemented simulation module, using the first output and simulating potential individual and ensemble interventions in the current autonomous actor network and providing a second output indicating effects of the simulations; a third computer-implemented ranking and selection module, using the second output and assembling a third output in the form of a set of the potential interventions ranked by feasibility and potential impact to increase collaboration in the autonomous actor network; a fourth computer-implemented intervention evaluation module, using the third output to test multiple of the potential interventions at one or more levels providing a fourth output; and a fifth computer-implemented update and correction module, using the second output and the fourth output to update and/or correct the current autonomous actor network representation.
G05B 13/04 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
Provided herein are methods of targeting PD-1+CD38hiCD8+ T cells to reduce apoptosis of white blood cells (e.g., lymphocytes). Further provided are methods of inducing apoptosis of white blood cells in a subject by using adoptive cell therapy with PD-1+CD38hiCD8+ T cells.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
9.
ETHER-À-GO-GO 1 (EAG1) POTASSIUM CHANNEL INHIBITORS AND USES THEREOF
The disclosure provides methods for the treatment of disorders associated with an increase in potassium channel activity using small molecule inhibitors, such as compounds that selectively bind to a Per-Arnt-Sim (PAS) domain of Ether-à-go-go 1 (EAG1) potassium channels. The disclosure also features pharmaceutical compositions comprising therapeutically effective amounts of the disclosed small molecule inhibitors.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A method is provided to reduce the counting times in radiation detection systems using machine learning, wherein the method comprises: receiving output data from a detector which is to detect a target material from a target body; analyzing the output data; identifying a material of interest from the analyzed output data; and controlling a source of the target material to prevent the source from harming the target body. An apparatus is also provided which comprises: a detector to detect radiation and to provide an output data in real-time; and a processor coupled to the detector, wherein the processor is to: receive the output data; analyze the output data; identify a material of interest from the analyzed output data; and control a source of the target material.
12346910131416181921232425261 23469101314161819212324252626 is A or K. In addition, use of the isolated MEF2 binding molecule to inhibit binding of histone deacetylase (HD AC) and MEF2 in a cell, and to inhibit HDAC- induced suppression of MEF2-dependent gene expression in a cell.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
12.
DETECTION OF LIVER DAMAGE USING CELL-FREE METHYLATED DNA
Methods of detecting cell-type-specific liver damage in a subject who received a liver transplant, the method comprising sequencing cell-free DNA (cfDNA) in a sample from the subject; determining cell-type from which the cfDNA originated by identifying methylation patterns in nucleotide sequence of one or more portions of the cfDNA that contains methylation sites, in which the cell-type is determined when the methylation pattern in the one or more portions is the same as a cell-type specific methylation pattern; and measuring the quantity of the cfDNA of the determined cell-type. The cell-type-specific liver damage is detected when the measured quantity of the cfDNA of the determined cell-type is greater as compared to a quantity of cfDNA of the determined cell-type in subjects without liver transplant damage. Methods also relating to treatment of subjects who received a liver transplant.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Compounds comprising a PAX3::FOXO1 fusion protein binding moiety, a bivalent linker, and an E3 ubiquitin ligase binding moiety. The compounds can be used to reduce PAX3::FOXO1 protein levels in a subject with fusion-positive rhabdomyosarcoma (FP-RMS), to ubiquitinate a PAX3::FOXO1 fusion protein in a cell, to treat FP-RMS in a subject in need thereof, and/or to treat a disease caused by the overexpression of PAX3::FOXO1 protein in a subject in need thereof.
Indolinone derivative compounds that act as EWS-PLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
C07D 209/38 - Atomes d'oxygène en positions 2 et 3, p. ex. isatine
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
15.
MACROENCAPSULATION DEVICE FOR CELL OR TISSUE TRANSPLANTATION
Macroencapsulation devices for transplanting cells or tissues are provided. In addition, macroencapsulation devices for local delivery of a drug to establish local immunosuppressive therapy are provided.
The present application provides for apparatuses, systems, and methods that can leverage the semantic embedding spaces of large language models. In example embodiments, a person's thought trajectory through semantic space can be represented as visible, namable geometric features. As a person engages in a thought process, the person can provide verbal input that can be analyzed to map the trajectory of the person's progression through semantic space and calculate and visually render the geometric features of the person's thought progression. Each idea within the thought process is a point along this trajectory. Ideas (points along the thought trajectory) can be mapped as the locations of word embeddings or sentence embeddings within a semantic space.
A method for fabricating a magnetic material with tunable magnetic properties, comprising the reactive sputtering of a Mn3N2 seed layer onto a substrate, annealing at a first temperature, depositing a Mn layer onto the Mn3N2 seed layer, cooling to a second lower temperature, and applying a capping layer to complete the magnetic material. The resulting structure includes a Si substrate with one or more MnNx layer(s) with tunable nitrogen contents, and a capping layer, exhibiting adjustable magnetic properties such as exchange bias. A single Mn4N layer can be formed with this method, so can multilayers of Mn3N2/Mn2N/Mn4N, or Mn2N/Mn4N, or other variations. Nitrogen partial pressure during deposition enables control of exchange bias by over an order of magnitude, while post-annealing reduces the bias by up to 70% through nitrogen migration into a neighboring tantalum layer. Voltage conditioning further tunes magnetic properties by driving nitrogen ions out of the Mn nitride layer, yielding an increased saturation magnetization and decreased exchange bias.
A physically sealed processing appliance for facilitating secure communications is described. The processing appliance includes a first data store with a pre-installed public encryption key associated with users of the appliance stored thereon, a processing store including instructions for creating a unique private/public encryption key pair upon an initial start-up of the processing appliance and for running a validation sequence to validate access authorization for the appliance users; and a second data store including at least one configuration template loaded onto the appliance by an access-validated user. The configuration template includes a list of peer appliances with which the processing appliance can communicate.
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
H04W 12/02 - Protection de la confidentialité ou de l'anonymat, p. ex. protection des informations personnellement identifiables [PII]
H04W 12/03 - Protection de la confidentialité, p. ex. par chiffrement
The present disclosure is directed to an analytical method for determining the concentration of a chiral alcohol in a sample and one or both of (i) the absolute configuration of the chiral alcohol in the sample, and (ii) the enantiomeric and/or the diastereomeric composition of the chiral alcohol in the sample. The present disclosure is also directed to an aryl or heteroaryl sulfonamide probe having the structure according to formula (I): Formula (I), where Ar, R1, R2, and n are as described herein, as well as to a kit for carrying out the analytical method described herein.
C07C 311/15 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
20.
PREVENTION OF METASTATIC OUTGROWTH USING TEAD INHIBITORS
Method of treating secondary cancer in a lung of a subject in need thereof, comprising administering a pharmaceutical composition comprising an effective amount of an inhibitor of transcriptional enhanced associate domain (TEAD) to the subject. In addition, methods of inhibiting growth of a secondary tumor in a lung of a subject in need thereof, of increasing number of T-cells at a secondary tumor in a lung of a subject in need thereof, of increasing number of alveolar macrophages in a lung of a subject in need thereof, of decreasing number of infiltrating monocytes/macrophages in a lung of a subject in need thereof, methods of reducing lung metastases in a subject in need thereof, method of inducing polarization of one or more M2 macrophages to M1 macrophages in the lung of a subject with lung cancer, and methods of activating IL12 signaling in lung of a subject with lung cancer.
Methods of treating cardiac hypertrophy or cardiomyocyte hypertrophy, or methods of inhibiting progression of heart failure in a subject in need thereof, in which the methods comprise administering a pharmaceutical composition comprising an effective amount of a conjugate comprising microRNA and a cardiac targeting peptide. In addition, methods of inhibiting expression of Ca2+/calmodulin-dependent protein kinase II delta or histone deacetylase 4 in cardiomyocytes, in which the methods comprise contacting the cardiomyocytes with a conjugate comprising microRNA and a cardiac targeting peptide. The microRNA may be mi RN A 106a. miRNA17, miRNA20a, or miRNA93.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
22.
TREATING NON-ALCOHOLIC STEATOHEPATITIS WITH CCK INHIBITORS
Provided herein are methods for treating nonalcoholic steatohepatitis (NASH) in a subject, comprising administering to a subject having NASH an effective amount of a CCK receptor inhibitor.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting public interest and awareness of health, nutrition, food, food portions, wellness, eating and drinking habits Educational services, namely, conducting classes, seminars, workshops and courses in the field of health and nutrition and distribution of course materials in connection therewith in printed or electronic format; Educational and entertainment services, namely, providing motivational and educational speakers; Educational and entertainment services, namely, providing motivational and educational speakers in the field of self- and personal improvement Providing mental health and wellness information; Providing information in the field of mental health and wellness via a website; Providing a web site featuring information in the field of mental health and wellness; Providing on-line information, news and commentary in the field of health and wellness relating to food, portion size, and nutrition
24.
APPARATUS AND METHODS FOR DETECTION AND QUANTIFICATION OF ELEMENTS IN MOLECULES
A method that includes introducing at least one analyte into a gas plasma; generating neutral species from atoms of the analyte in the gas plasma; preferentially transporting the neutral species downstream of the gas plasma relative to any ions produced in the gas plasma; and reacting the neutral species of the analyte with at least one reagent ion downstream of the plasma resulting in ion species of the analyte, wherein the at least one reagent ion is supplied by an independent ion source.
Disclosed herein are aspects of a scaffold for tissue regeneration, the scaffold comprising a first component comprising one or more biocompatible materials; and a second component comprising a pectin-containing sacrificial template, wherein the second component is intermittently associated with the first component. In certain aspects, the scaffold may further comprise a disassociating agent for dissolving the second component. Also, disclosed herein is a method for making a scaffold for tissue regeneration, the method comprising providing a first feed to a first nozzle and a second feed to a second nozzle, the first feed comprising one or more biocompatible materials, the second feed comprising pectin, pectin derivatives, or a combination thereof; and obtaining a composition comprising a first component and a second component, the first component comprising the one or more biocompatible materials, and the second component comprising a pectin-containing sacrificial template that is intermittently associated with the first component.
A61L 27/48 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges macromoléculaires
A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
Methods of detecting DNA damage in tissue by an agent or of determining whether an agent is genotoxic. The methods comprise subjecting a transgenic zebrafish to the agent, in which the genome of the transgenic zebrafish comprises (i) a first nucleic acid construct encoding at least a first promoter, target site, and a first fluorescent protein, and (ii) a second nucleic acid construct encoding at least a second promoter, a DNA-binding domain, and an effector domain; and detecting fluorescence in the transgenic zebrafish. The DNA-binding domain is configured to bind to the target site on the first nucleic acid construct, and the effector domain is configured to inhibit transcription of the first fluorescent protein in the absence of damage to the effector domain caused by the agent. Detection of fluorescence indicates DNA damage or that the agent is genotoxic.
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A01K 67/0275 - Vertébrés modifiés génétiquement, p. ex. transgéniques
The Board of Regents of The University of Texas System (USA)
Inventeur(s)
Debad, Jeff
Gatson, Joshua
Burns, Mark
Biesso, Arianna
Abrégé
The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1β, IL-2, IL-6, IL-10, IL-22, IP-10, TNFα, TSLP, NFL, and/or NFH.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 21/66 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité électriquement, p. ex. par électroluminescence
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
28.
METHODS AND COMPOSITIONS FOR DIAGNOSING AND SELECTIVELY TREATING OR PREVENTING URINARY TRACT INFECTION AND UROBIOME DYSBIOSIS
A method of treating or preventing urobiome dysbiosis in a subject in need thereof is described. The method includes intravesicularly administering to the subject a therapeutically effective amount of two or more of an antimicrobial agent, and antispasmodic agent, and a live biotherapeutic product (LBP). Additional methods of determining the likelihood of symptomatic urinary tract infection (UTI) in a subject and selecting treatment for a UTI in a subject are described, as well as Live Biotherapeutic Product (LBP) compositions and the use thereof in methods for the treatment and/or prevention of UTI in a subject.
Systems and processes described herein are for monitoring data records and predicting changes to coded values in the data records. More specifically, this disclosure relates to predicting and potentially preventing anomalies represented in data records by predicting values of entries to be added to the data records and causing a prophylactic response to the predicted anomaly to prevent the anomaly from occurring.
Extracellular vesicles and/or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Methods of transplanting target cells into a subject in need thereof. The methods generally comprise creating a sealed transplantation space by attaching an acellular membrane to the surface of a visceral organ or tissue in the subject in a manner such that a sealed space is created between the surface of the visceral organ or tissue and the membrane, and inserting a mixture of support cells and the target cells into the sealed transplantation space.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
Methods of treating obesity, reducing body weight, or inhibiting weight gain in a subject in need thereof, the methods comprising administering to the subject a pharmaceutical composition comprising an effective amount of a large amino acid transporter small subunit1 (LAT1) inhibitor. The LAT1 inhibitor may be a small molecule, such as JPH203 or OKY-034.
Provided herein are methods and uses of treating or preventing an a-Synucleinopathy in a subject comprising administration of a tyrosine kinase inhibitor.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
34.
Method and system for assessing drug efficacy using multiple graph kernel fusion
Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p. ex. leurs effets secondaires ou leur usage prévu
35.
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS
Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a myodegenerative disease, a prion disease or a lysosomal storage disease in a subject.
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A method of fabricating high magnetic anisotropy materials using a metallic high entropy alloy is described in this disclosure. Targets of metals or targets of alloys comprising at least one elemental ferromagnetic material are used in a sputtering tool to deposit on a substrate thin films of high entropy alloys. The sputtering targets may be elemental targets or they may comprise multiple metals. In addition, targets of materials such as boron, platinum, or aluminum may be included in the sputtering process to enhance magnetic properties of the resultant thin films. The sputtering may take place by co-sputtering multiple targets simultaneously or by alternatively sputtering layers from the targets. After sputtering the materials are heated through a rapid thermal annealing process to a high temperature, which facilitates the formation of the desired crystalline phases which exhibit high magnetocrystalline anisotropy.
H01F 41/18 - Appareils ou procédés spécialement adaptés à la fabrication ou à l'assemblage des aimants, des inductances ou des transformateursAppareils ou procédés spécialement adaptés à la fabrication des matériaux caractérisés par leurs propriétés magnétiques pour appliquer des pellicules magnétiques sur des substrats par pulvérisation cathodique
The Board of Regents of the University of Oklahoma (USA)
Inventeur(s)
Brown, Milton L.
Kong, Yali
Houchen, Courtney
Sureban, Sripathi M.
Chandrakesan, Parthasarathy
Abrégé
Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.
Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61P 39/00 - Agents protecteurs généraux ou antipoisons
38.
A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC LINKERS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
Histone deacetylases inhibitors (HDACbls) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease including peripheral neuropathies such as Charcot Marie Tooth disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
39.
LOW-TEMPERATURE ELECTROCHEMICAL DIRECT METHANE REFORMING TO PRODUCE HYDROGEN
Provided herein is a low-temperature methane steam reformer comprising a proton-exchanged membrane fuel cell comprising an anode and a cathode, wherein hydrogen is produced at the cathode, wherein the fuel cell comprises a metal- membrane-assembly utilizing platinum electrocatalysts. Also provided are methods of producing hydrogen using the low temperature methane reformer, comprising feeding methane to the low temperature methane reformer at a relative humidity (RH) of 60% to 100%; and catalyzing the reaction at temperature of 30°C and 120°C or less and back pressure of 90 kPa and 1000 kPa or less.
C25B 11/04 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par le matériau
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
G01N 30/04 - Préparation ou injection de l'échantillon à analyser
Technologies are described for retrieving documents using image representations in the documents and is based on intra-image features. The identification of elements within an image representation can allow for deeper understanding of the image representation and for better relating image representations based on their intra-image features. The intra-image features present in image representations can be used in searches. Search results can further be reranked to improve search results. For example, reranking can allow search results to conform to intra-image dominant image features.
G06F 16/532 - Formulation de requêtes, p. ex. de requêtes graphiques
G06F 16/538 - Présentation des résultats des requêtes
G06F 16/56 - Recherche d’informationsStructures de bases de données à cet effetStructures de systèmes de fichiers à cet effet de données d’images fixes en format vectoriel
G06F 16/583 - Recherche caractérisée par l’utilisation de métadonnées, p. ex. de métadonnées ne provenant pas du contenu ou de métadonnées générées manuellement utilisant des métadonnées provenant automatiquement du contenu
G06V 10/26 - Segmentation de formes dans le champ d’imageDécoupage ou fusion d’éléments d’image visant à établir la région de motif, p. ex. techniques de regroupementDétection d’occlusion
G06V 10/74 - Appariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques
G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
G06V 10/771 - Sélection de caractéristiques, p. ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 20/70 - Étiquetage du contenu de scène, p. ex. en tirant des représentations syntaxiques ou sémantiques
41.
LNA GAPMERS INHIBIT GROWTH OF CCK-BR POSITIVE CANCER
THE U.S.A., as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Smith, Jill P.
Stern, Stephan
Kularatne, Ruvanthi
Shivapurkar, Narayan
Abrégé
An antisense oligonucleotide (ASO) 14 to 20 nucleotides in length that specifically hybridizes with a gastrin mRNA molecule, wherein the ASO comprises at least one locked nucleic acid (LNA) nucleotide at each of the 5' and 3' termini.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
44.
Apparatus and process for optimizing radiation detection counting times using machine learning
A method is provided to reduce the counting times in radiation detection systems using machine learning, wherein the method comprises: receiving output data from a detector which is to detect a target material from a target body; analyzing the output data; identifying a material of interest from the analyzed output data; and controlling a source of the target material to prevent the source from harming the target body. An apparatus is also provided which comprises: a detector to detect radiation and to provide an output data in real-time; and a processor coupled to the detector, wherein the processor is to: receive the output data; analyze the output data; identify a material of interest from the analyzed output data; and control a source of the target material.
Embodiments of the present systems and methods may provide techniques for synthesizing speech in any voice in any language in any accent. For example, in an embodiment, a text-to-speech conversion system may comprise a text converter adapted to convert input text to at least one phoneme selected from a plurality of phonemes stored in memory, a machine-learning model storing voice patterns for a plurality of individuals and adapted to receive the at least one phoneme and an identity of a speaker and to generate acoustic features for each phoneme, and a decoder adapted to receive the generated acoustic features and to generate a speech signal simulating a voice of the identified speaker in a language.
G10L 13/047 - Architecture des synthétiseurs de parole
G10L 13/08 - Analyse de texte ou génération de paramètres pour la synthèse de la parole à partir de texte, p. ex. conversion graphème-phonème, génération de prosodie ou détermination de l'intonation ou de l'accent tonique
46.
C-KIT INHIBITORS AND USES FOR TREATING AND PREVENTING INFLAMMATORY CONDITIONS
Disclosed are small molecule c-kit inhibitors useful in reducing or eliminating mast cell mediated inflammation. Pharmaceutical formulations containing the c-kit inhibitors are also disclosed. Additionally, methods of treating or preventing a condition, disorder, or disease using the c-kit inhibitors or pharmaceutical formulations thereof are disclosed. The condition, disorder, or disease may be an inflammatory condition, including flares of the inflammatory condition. Exemplary inflammatory conditions relevant to this disclosure include, but are not limited to, mastocytosis, mast cell activation syndrome, hereditary alpha tryptasemia, urticaria, Lyme disease, mast cell leukemia, chronic obstructive pulmonary disease, long COVID, asthma, inflammatory bowel disease, arthritis, allergy, and gout.
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
47.
TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS
Methods for the treatment of cutaneous vascular conditions and cutaneous proliferative conditions are provided. The methods employ topical administration of mammalian target of rapamycin (mTOR) inhibitors such as sirolimus (rapamycin) and everolimus. Conditions treatable by the disclosed methods include venolymphatic malformations, acne, acne rosacea, periorificial dermatitis, acne vulgaris, cutaneous capillary malformation-arteriovenous malformation (CM-AVM) syndrome, RASopathies, Langerhans cell histiocytosis, non-Langerhans cell histiocytosis, scars, hypertrophic or keloidal scars, Proteus syndrome, PIK3CA-related overgrowth spectrum (PROS), PTEN hamartoma tumor syndromes, cutaneous malignancies and tumors associated with PI3K/AKT/mTOR mutations, keratodermas, acanthosis nigricans, Birt-Hogg-Dubé syndrome, Brooke-Speigler syndrome, cylindromas, and epidermal nevi. Also provided are formulations and pharmaceutical compositions having mTOR inhibitor as principal therapeutically active ingredient useful in practicing the methods.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
48.
SILK FIBROIN-CONTAINING COMPOSITION AND METHODS OF USE THEREOF
Provided are compositions comprising silk fibroin, perfluorocarbon (PFC), and surfactant, and methods of use thereof. The compositions can further comprise a drug, an antibody, or a vaccine. Compositions of the invention are useful in the treatment of certain lung diseases and conditions, including in particular those characterized by surfactant deficiency. Compositions of the invention are particularly useful in the treatment of respiratory distress syndrome (RDS). Also provided are methods for making the compositions, and kits comprising components of the compositions.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A machine-learning tool learns from sensors' data of a nuclear reactor at steady state and maps them to controls of the nuclear reactor. The tool learns all given ranges of normal operation and responses for corrective measures. The tool may train another learning tool (or the same tool) that forecasts the behavior of the reactor based on real-time changes (e.g., every 10 seconds). The tool implements an optimization technique for differing half-life materials to be placed in the reactor. The tool maximizes isotope production based on optimal controls of the reactor.
A method and system are described for improving the speed and efficiency of obtaining conversational search results. A user may speak a phrase to perform a conversational search or a series of phrases to perform a series of searches. These spoken phrases may be enriched by context and then converted into a query embedding. A similarity between the query embedding and document embeddings is used to determine the search results including a query cutoff number of documents and a cache cutoff number of documents. A second search phrase may use the cache of documents along with comparisons of the returned documents and the first query embedding to determine the quality of the cache for responding to the second search query. If the results are high-quality then the search may proceed much more rapidly by applying the second query only to the cached documents rather than to the server.
This invention provides methods of treating neurologic disorders including, but not limited to, synucleinopathic disorders (including Parkinson's Disease), Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS) disease and Huntington's disease. The methods include delivery into neuronal cells of antibody or antibody fragment(s), or nucleic acids encoding intrabodies, such as single domain antibodies and single chain Fv antibody fragments against proteins associated with such neurologic disorders, suitably using a liposomal complex that crosses the blood brain barrier and can deliver the payload into neuronal cells. This invention also provides methods wherein a delivered nucleic acid encodes a protein which is a nanobody targeted to a neuronal postsynaptic scaffolding protein Homer1 that is present at partially overlapping sets of excitatory synapses, and is associated with Fragile X Syndrome (FXS) and Deafness, Autosomal Dominant 68 (DFNA68).
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
52.
DOCUMENT SEARCH FOR DOCUMENT RETRIEVAL USING 3D MODEL
Technologies are described for reconstructing physical objects which are preserved or represented in pictorial records. The reconstructed models can be three-dimensional (3D) point clouds and can be compared to existing physical models and/or other reconstructed models based on physical geometry. The 3D point cloud models can be encoded into one or more latent space feature vector representations which can allow both local and global geometric properties of the object to be described. The one or more feature vector representations of the object can be used individually or in combination with other descriptors for retrieval and classification tasks. Neural networks can be used in the encoding of the one or more feature vector representations.
G06F 16/56 - Recherche d’informationsStructures de bases de données à cet effetStructures de systèmes de fichiers à cet effet de données d’images fixes en format vectoriel
G06T 17/00 - Modélisation tridimensionnelle [3D] pour infographie
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 40/16 - Visages humains, p. ex. parties du visage, croquis ou expressions
53.
System for providing validation of deep learning based prescription efficacy
A method and system for merging healthcare records across multiple locations is presented. The method first creates anonymized healthcare records by removing personally identifiable information. The method then converts each record into an embedding and appends a site locator identifying only the originator of the healthcare record. Then these embeddings are combined with similarly processed embeddings from multiple sites to create a merged database of embeddings derived from patient healthcare records. A classifier is trained to predict likely outcomes based on the merged database of embeddings. For a new patient, the corresponding healthcare record is converted to an embedding and the merged database of embeddings is then searched for a most similar patient and a treatment is recommended for the new patient, based on the prediction of the classifier.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
54.
METHODS AND COMPOSITIONS FOR TREATING OBESITY, SKIN DISORDERS, AND/OR EYE DISORDERS
Method of determining if a subject has suffered tissue damage from exposure to a toxic agent. The method comprises sequencing cell-free DNA (cfDNA) in a biospecimen from the subject; determining cellular origin of the cfDNA by identifying methylation patterns in one or more portions of the sequence of the cfDNA that contains methylation sites, in which the cellular origin of the cfDNA is determined when the methylation pattern in the one or more portions is the same as a known cell-type specific methylation patterns; measuring the quantity of the cfDNA of the determined cellular origin, and comparing the measured quantity of the cfDNA of the determined cellular origin with a normal quantity of cfDNA of the determined cellular origin. A greater quantity of the measured cfDNA of the determined cellular origin is indicative that the subject has suffered tissue damage.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
56.
COMBINED DETERMINATION OF THE CONCENTRATION AND ENANTIOMERIC COMPOSITION OF CHIRAL COMPOUNDS USING SINGLE CHIROPTICAL ASSAY
The present invention relates to the analytical methods for determining the concentration of the analyte in the sample and one or both of (i) the absolute configuration of the analyte in the sample, and (ii) the enantiomeric and/or the diastereomeric composition of the analyte in the sample and the kit for carrying out the analytical method. The present invention also relates to the use of a chromophore probe in such analytical methods.
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
C09B 57/00 - Autres colorants synthétiques de structure connue
57.
METHODS FOR PRODUCING A SUPER CENTRAL MEMORY CD8 T CELL SUBTYPE BY POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITION AND USES THEREOF
The present invention provides methods of identifying neopeptides in abnormal cells, with the methods comprising sequencing long-read messenger RNA (mRNA) isolated from the abnormal cells, identifying splice variants that could be generated from the sequenced long-read mRNA, determining if the abnormal cells contain neopeptides that correlate with the identified splice variants. The methods may also comprise identifying at least one neoantigen on the neopeptides that are present in the abnormal cells.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Technologies are described for reconstructing facial models which are preserved images or images captured from security cameras. The reconstructed models can be three-dimensional (3D) point clouds and can be compared to existing facial models and/or other reconstructed models based on physical geometry. The 3D point cloud models can be encoded into one or more latent space feature vector representations which can allow both local and global geometric properties of a face to be described. The one or more feature vector representations of a target face can be used individually or in combination with other descriptors for recognition, retrieval, and classification tasks. Neural networks can be used in the encoding of the one or more feature vector representations.
G06F 16/56 - Recherche d’informationsStructures de bases de données à cet effetStructures de systèmes de fichiers à cet effet de données d’images fixes en format vectoriel
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 30/418 - Appariement de documents, p. ex. d’images de documents
G06V 40/16 - Visages humains, p. ex. parties du visage, croquis ou expressions
60.
ASSAY AND METHODS FOR USE IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS
Extracellular vesicles and/or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
61.
Generating hypotheses and recognizing events in data sets
A hypotheses generation and event recognition system that enables event recognition by analyzing documents to construct one or more qualitative metrics (e.g., frequency of keywords, changes in sentiment, occurrence of ontological terms, evolution of topics, etc.), establishing a baseline for the qualitative metric(s), and outputting changes to that baseline for display. In aggregate, those qualitative metrics comprise temporal and/or spatial signals that, when combined, define signatures of events of interest. Accordingly, the user and/or the system may identify an event of interest based on the change in baseline. The system may further provide functionality to generate hypotheses by coding data according to an ontology, populating an ontology space, and using an optimization algorithm to rank points or neighborhoods in the coded ontology space. The system may further store links between ontological terms and qualitative metrics to provide functionality to test generated hypotheses that include those linked ontological terms.
A method of detecting donor cell death in a subject receiving foreign biological material from a donor. The method comprises sequencing cfDNA in a biospecimen from the subject; determining cellular origin of the cfDNA by identifying methylation patterns in the sequence of the cfDNA and comparing the methylation patterns in the sequence of the cfDNA to known methylation patterns associated with different cell types; and determining source origin of the cfDNA by genotyping the cfDNA and identifying whether the cfDNA originates from the foreign biological material or from the subject. Cell death is detected when the cfDNA has both a cellular origin of the type of foreign biological material that was received from the donor, and a source origin of the donor.
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
63.
TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS LESIONS
The USA as represented by the Secretary, Department of Health and Human Services (USA)
Inventeur(s)
Smith, Jill P.
Stern, Stephan
Abrégé
A method that includes detecting the presence of a pancreatic intraepithelial neoplasia lesion in a subject in vivo comprising administering to the subject a construct, or a pharmaceutically acceptable salt thereof, wherein the construct comprises:
(a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized;
(b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and
(c) a detectable moiety complexed with, or conjugated to, the poly(L-lysine) of the polymer moiety,
wherein the construct is neutralized.
The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
65.
QUANTITATIVE CHIRALITY AND CONCENTRATION SENSING OF CHIRAL ANALYTES USING QUINONES, (HETERO)ARYL ISOCYANATES, AND/OR (HETERO)ARYL ISOTHIOCYANATES
An analytical method is disclosed that includes the steps of: providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms; providing a probe selected from the group consisting of quinones and analogs thereof, (hetero)aryl isocyanates and analogs thereof, and (hetero)aryl isothiocyanates and analogs thereof; contacting the sample with the probe under conditions to permit covalent binding of the probe to the analyte, if present in the sample; and determining, based on any binding that occurs, the absolute configuration of the analyte in the sample and/or the concentration of the analyte in the sample and/or the enantiomeric and/or the diastereomeric composition of the analyte in the sample.
G01N 21/33 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
A metal foam-based filtration system and method for removing sub-micron particles and contaminants from a gas or fluid flow with the use of ultralow density metal nanowire meshes that have nanometer to micron scale pores for trapping air/fluid-borne particulates. Filters can use metal foams and coated metal foams alone or in tandem. The size and density of pores in the foam can be adjusted with synthesis conditions. Foams with pore size gradients promote the trapping of different sized particulates at different regions of a foam. Multiple rounds of electrodeposition increase the surface area and curvature of a nanowire mesh and strengthen the mesh. A metal and/or a coated metal foam can act as a catalyst or substrate for absorption or adsorption. Varying certain parameters can also impact the quality of the foam. Additionally, nanoparticles of about 300 nm in size can be directly incorporated into the foams.
B01D 39/20 - Autres substances filtrantes autoportantes en substance inorganique, p. ex. papier d'amiante ou substance filtrante métallique faite de fils métalliques non-tissés
B01D 46/24 - Séparateurs de particules utilisant des corps filtrants creux et rigides, p. ex. appareils de précipitation de poussières
67.
Non-Invasive and Passive Transdermal Drug Delivery Patch For Parkinson's Disease
A flexible drug delivery patch is described for non-invasively delivering macromolecular drugs directly to the circulatory system of a user. The patch includes multiple sealed reservoirs formed therein, the sealed reservoirs containing the macromolecular drugs which are entrapped within one of a dissolvable polymer matrix using one of nanoparticles or nanofibers or a thermo-responsive hydrogel. The macromolecular drugs being released from the sealed reservoirs and the entrapping material by activating one or more electrically addressable microheating units.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
68.
NON-TOXIC PLGA COMPOSITIONS AND METHODS OF MAKING AND USING SAME
in vitroin vivoin vivo release of drugs incorporated therein. Also provided are methods for making and using the PLGA constructs and compositions and pharmaceutical compositions comprising same.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
69.
Method and system for assessing drug efficacy using multiple graph kernel fusion
Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p. ex. leurs effets secondaires ou leur usage prévu
70.
USE OF RAGE INHIBITORS TO TREAT CANCER-RELATED COGNITIVE DECLINE
A method of treating cancer-related cognitive decline (CRCD) in a patient, in which the method comprises administering to the patient an effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE). The inhibitor of RAGE may be administered as a single dose or as multiple doses before the administration of the cancer therapy, during the administration of the cancer therapy, after the administration of the cancer therapy, or a combination thereof. Administration of the inhibitor of RAGE may improve attention, processing speed, executive functioning, learning, memory, or a combination thereof, of the patient as compared to patients who are not administered the inhibitor of RAGE.
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Provided herein are methods for treating fibrosis (e.g. pancreatic fibrosis) in a subject. Some methods comprise administering to a subject having pancreatic fibrosis an effective amount of a CCK receptor inhibitor.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided herein are methods of targeting PD-1+CD38hiCD8+T cells to reduce apoptosis of white blood cells (e.g., lymphocytes). Further provided are methods of inducing apoptosis of white blood cells in a subject by using adoptive cell therapy with PD-1+CD38hiCD8+ T cells.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
73.
FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION
Systems and methods are disclosed for the treatment of cancer. Specifically, techniques are disclosed for treating cancer through the administration of genetically modified immune cells that overexpress fibroblast activation protein. In other embodiments, the techniques include the treatment of cancer through the administration of fibroblast activation protein inhibitors to the tumor site.
Novel ubiquitin specific protease 13 (USP13) inhibitors are provided, along with methods for their use. The USP13 inhibitors described herein are useful in treating and/or preventing USP13-related diseases, such as neurodegenerative diseases and cancer. Also provided are methods for inhibiting USP13 in a cell using the compounds and compositions described herein.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 215/233 - Atomes d'oxygène liés en position 2 ou 4 un seul atome d'oxygène qui est lié en position 4
C07D 215/44 - Atomes d'azote liés en position 4 avec des radicaux aryle liés auxdits atomes d'azote
C07D 311/68 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des substituants autres que des atomes d'oxygène ou de soufre en position 2 ou 4 avec des atomes d'azote liés directement en position 4
75.
ENHANCING CHEMOTHERAPY IN MEDULLOBLASTOMA AND GLIOBLASTOMA WITH HIGH BASAL p53 LEVELS
Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
76.
Method and system for a parametric speech synthesis
Embodiments of the present systems and methods may provide techniques for synthesizing speech in any voice in any language in any accent. For example, in an embodiment, a text-to-speech conversion system may comprise a text converter adapted to convert input text to at least one phoneme selected from a plurality of phonemes stored in memory, a machine-learning model storing voice patterns for a plurality of individuals and adapted to receive the at least one phoneme and an identity of a speaker and to generate acoustic features for each phoneme, and a decoder adapted to receive the generated acoustic features and to generate a speech signal simulating a voice of the identified speaker in a language.
G10L 13/047 - Architecture des synthétiseurs de parole
G10L 13/08 - Analyse de texte ou génération de paramètres pour la synthèse de la parole à partir de texte, p. ex. conversion graphème-phonème, génération de prosodie ou détermination de l'intonation ou de l'accent tonique
G10L 13/10 - Règles de prosodie dérivées du texteIntonation ou accent tonique
G10L 21/00 - Techniques de traitement du signal de parole ou de voix pour produire un autre signal audible ou non audible, p. ex. visuel ou tactile, afin de modifier sa qualité ou son intelligibilité
G10L 25/00 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes
Provided herein are methods for diagnosing and staging fibrosis associated with a disease state in a subject, such as liver disease or cancer. Also provided are methods for monitoring treatment efficacy. The methods include measuring the level of one or more miRNAs selected from the group consisting of miR-185- 5p, miR-378a-3p, miR708-5p, miR-346-5p, miR302d-3p, miR-103-3p, miR-142-5p, miR126, miR-711, miR135b-5p, miR-21a-5p, miR-27a-3p, miR30c-2-3p, miR-9-5p, and miR29b-3p in the sample to obtain an expression profile indicative of the presence, absence, or extent of fibrosis.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
78.
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION
The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) polymerase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-Iα) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-Iα or AKT3 and/or higher acetylation levels of PGC-Iα in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
79.
COMPOSITIONS AND METHODS FOR ENHANCING T CELL PENETRATION OF TUMORS AND CANCERS
Provided are methods for enhancing anti-tumor and/or anti-cancer immunotherapies. In some embodiments, the methods include administering to a subject in need thereof a composition that includes a conjugate that includes a gastrin immunogen conjugated to an immunogenic carrier, optionally conjugated via a linker, in an amount and via a route sufficient to enhance entry into the tumor and/or cancer of an anti-tumor T cell, whereby an anti- and/or anti-cancer tumor immunotherapy is enhanced. Also provided are pharmaceutical compositions that have the conjugates for use in treating tumors and cancers, methods for treating tumors and/or cancers, and methods for sensitizing solid tumors and/or cancers in subjects to chimeric antigen receptor-T (CAR-T) cell therapies.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
80.
USE OF CONJUGATES OF MICRORNA AND CARDIAC TARGETING PEPTIDES FOR TREATING HEART FAILURE
Methods of treating cardiac hypertrophy or cardiomyocyte hypertrophy, or methods of inhibiting progression of heart failure in a subject in need thereof, in which the methods comprise administering a pharmaceutical composition comprising an effective amount of a conjugate comprising microRNA and a cardiac targeting peptide. In addition, methods of inhibiting expression of Ca2+/calmodulin-dependent protein kinase II delta or histone deacetylase 4 in cardiomyocytes, in which the methods comprise contacting the cardiomyocytes with a conjugate comprising microRNA and a cardiac targeting peptide. The microRNA may be mi RN A 106a. miRNA17, miRNA20a, or miRNA93.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
81.
Specialized computing environment for co-analysis of proprietary data
A specialized computing environment that includes hardware and data security features to enable competitive organizations to co-analyze proprietary data without revealing the underlying proprietary data to unauthorized users. Proprietary data are stored in volatile memory, which may be automatically erased according to pre-stored criteria. The analysis is performed automatically by a processing unit without human intervention. Analytical results are sanitized (e.g., using data masking) to prevent the analytical result from being tracible to any particular data source. Sanitized analytical results are output without outputting the underlying proprietary data (except to users authorized to validate analytical results). The computing environment is enclosed within a secure enclosure (e.g., a steel box with a lock), does not include any peripheral devices outside the secure enclosure, does not communicate wirelessly, and does not have hardware ports accessible from outside the secure enclosure (except, in some embodiments, a wired connection for a web server).
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
G06F 16/215 - Amélioration de la qualité des donnéesNettoyage des données, p. ex. déduplication, suppression des entrées non valides ou correction des erreurs typographiques
G06F 21/00 - Dispositions de sécurité pour protéger les calculateurs, leurs composants, les programmes ou les données contre une activité non autorisée
A gait analysis system, which includes a neural network with a recurrent neural network layer and a fully connected layer, that receives sensor data indicative of an individual's gait and outputs an assessment regarding the individual's health. The neural network is trained using training data indicative of abnormal gaits and normal gaits. To analyze the training data and the sensor data, the recurrent neural network layer parses each piece of data into a series of windows and analyzes each window in series to generate a context vector characterizing each window and the previously analyzed windows. The fully connected layer, having been trained to differentiate between normal gaits and abnormal gaits based on context vectors characterizing the training data, is used to generate a final assessment characterizing the user gate as normal or abnormal using one or more of the context vectors characterizing the sensor data.
Methods of treating a lipid disorder or skin disorder, of increasing lipid secretion from sebaceous glands, or of reducing adipose tissue in a subject in need thereof, the methods comprising administering to the subject a pharmaceutical composition comprising an effective amount of N-acetylcysteine. The lipid disorder may be fatty liver disease, hyperlipidemia, obesity, or lipodystrophy.
Methods of treating obesity, reducing body weight, or inhibiting weight gain in a subject in need thereof, the methods comprising administering to the subject a pharmaceutical composition comprising an effective amount of a large amino acid transporter small subunit1 (LAT1) inhibitor. The LAT1 inhibitor may be a small molecule, such as JPH203 or OKY-034.
Provided herein are compositions comprising CD4+ stem cell like memory T (TSCM) cells and their uses in the treatment of cancer, infection and autoimmune disorders.
The Board of Regents of the University of Oklahoma (USA)
Inventeur(s)
Brown, Milton L.
Kong, Yali
Houchen, Courtney
Sureban, Sripathi M.
Chandrakesan, Parthasarathy
Abrégé
Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I
or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61P 39/00 - Agents protecteurs généraux ou antipoisons
87.
SYSTEMS AND METHODS FOR REAL-TIME DETECTION AND CAPTURE OF INVASIVE CELL SUBPOPULATIONS FROM CO-CULTURES
Systems and methods are disclosed for identifying invasive cells. In certain embodiments, the system is comprised of a first chamber comprised of media, and the first plurality of cells are healthy cells, diseased cells, or a mixture of both, a second chamber comprised of a filtration membrane and a third chamber comprised of media, and a second plurality of cells. The second plurality of cells produces one or more chemoattractants or chemorepellents, and the first, second, and third chambers are clipped together to form a chamber array. The chamber array is mounted to an electrical cell impedance sensing reader, and impedance readouts are collected from the electrical cell impedance sensing reader at predetermined time intervals. Then, invasive cells are extracted from under the filtration membrane of the second chamber, wherein the extracted invasive cells are characterized using the collected impedance readouts normalized over a predetermined time period.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
A method of fabricating high magnetic anisotropy materials using a metallic high entropy alloy is described in this disclosure. Targets of metals or targets of alloys comprising at least one elemental ferromagnetic material are used in a sputtering tool to deposit on a substrate thin films of high entropy alloys. The sputtering targets may be elemental targets or they may comprise multiple metals. In addition, targets of materials such as boron, platinum, or aluminum may be included in the sputtering process to enhance magnetic properties of the resultant thin films. The sputtering may take place by co-sputtering multiple targets simultaneously or by alternatively sputtering layers from the targets. After sputtering the materials are heated through a rapid thermal annealing process to a high temperature, which facilitates the formation of the desired crystalline phases which exhibit high magnetocrystalline anisotropy.
G11B 5/00 - Enregistrement par magnétisation ou démagnétisation d'un support d'enregistrementReproduction par des moyens magnétiquesSupports d'enregistrement correspondants
G11B 5/39 - Structure ou fabrication de têtes sensibles à un flux utilisant des dispositifs magnétorésistifs
G11B 5/64 - Supports d'enregistrement caractérisés par l'emploi d'un matériau spécifié comportant uniquement le matériau magnétique, sans produit de liaison
G11B 5/851 - Revêtement d'un support avec une couche magnétique par pulvérisation cathodique
89.
Caching historical embeddings in conversational search
A method and system are described for improving the speed and efficiency of obtaining conversational search results. A user may speak a phrase to perform a conversational search or a series of phrases to perform a series of searches. These spoken phrases may be enriched by context and then converted into a query embedding. A similarity between the query embedding and document embeddings is used to determine the search results including a query cutoff number of documents and a cache cutoff number of documents. A second search phrase may use the cache of documents along with comparisons of the returned documents and the first query embedding to determine the quality of the cache for responding to the second search query. If the results are high-quality then the search may proceed much more rapidly by applying the second query only to the cached documents rather than to the server.
Histone deacetylases inhibitors (HDACbls) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease including peripheral neuropathies such as Charcot Marie Tooth disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
Histone deacetylases inhibitors (HDACbls) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease including peripheral neuropathies such as Charcot Marie Tooth disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/4162 - 1,2-Diazoles condensés avec des systèmes hétérocycliques
92.
COMBINATION THERAPY OF ARTEMISININ-RELATED COMPOUNDS AND HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF HPV-RELATED BENIGN, PREMALIGNANT, AND MALIGNANT DISEASES
Methods of treating human papillomavirus (HPV)-induced conditions, HPV-induced lesions, or HPV-infected cells. The method involves administering one or more artemisinin-related compounds and one or more histone deacetylase (HDAC) inhibitors. In addition, treatment regimens involving the use of artemisinin-related compounds and HDAC inhibitors, and kits comprising pharmaceutical compositions of artemisinin-related compounds and HDAC inhibitors.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Provided herein are compositions and methods for the treatment and prevention of cadherin-11 (CDH11) related diseases. The compositions include CDH11 inhibitors that are formulated for use in combination with chemotherapy and/or immunotherapy, to treat or prevent cancer, fibrosis, and autoimmune diseases.
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
94.
SITE- AND STRUCTURE-SPECIFIC CORE FUCOSYLATION IN LIVER DISEASE
The instant disclosure provides methods of detecting N-glycopeptides in a sample by contacting the sample with one or more exoglycosidases and detecting the N-glycopeptides by mass spectrometry. Also provided are methods of detecting the presence or progression of a liver disease and treating said liver disease.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
95.
Methods of Treating Residual Lesions of Vascular Anomalies
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present application relates to an analytical method that includes providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms, providing certain probes; and providing an indicator. The sample is contacted with an excess of the probe under conditions to permit irreversible covalent binding of the probe to the analyte, if present in the sample. The sample is contacted with the indicator under conditions to permit covalent binding of the indicator to any excess probe that is not bound to the analyte. Based on any binding that occurs between the analyte and probe, the absolute configuration of the analyte in the sample and/or the enantiomeric composition of the analyte in the sample using a chiroptical technique is/are determined. Based on any binding that occurs between the indicator and probe, the concentration of the analyte in the sample is determined using a non-chiroptical technique.
G01N 21/63 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité optiquement
Methods of generating a population of tumor cells, such as circulating tumor cells (CTCs) isolated from fluid from a subject. The methods involve collecting a fluid sample containing the tumor cells from the subject, and culturing the tumor cells in the fluid sample in a three-dimensional cell culture, wherein the three-dimensional cell culture comprises at least one inhibitor of Rho-kinase to generate the population of CTCs. If the fluid is whole blood or contains blood, the method may also involve subjecting the fluid sample to density gradient separation to separate the tumor cells from the fluid prior to culturing. In addition, methods of identifying a candidate treatment for a subject having a condition marked by the presence of tumor cells, methods of monitoring in a subject the persistence, regression, or progression of a disease or condition marked by the presence of tumor cells, and methods of generating a cell line of tumor cells.
The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 21/33 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
C07C 309/05 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé contenant au moins deux groupes sulfo liés au squelette carboné
C07C 309/73 - Esters d'acides sulfoniques ayant des atomes de soufre de groupes sulfo estérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné à des atomes de carbone de cycles aromatiques à six chaînons non condensés
C07C 309/65 - Esters d'acides sulfoniques ayant des atomes de soufre de groupes sulfo estérifiés liés à des atomes de carbone acycliques d'un squelette carboné saturé
99.
NON-INVASIVE AND PASSIVE TRANSDERMAL DRUG DELIVERY PATCH FOR PARKINSON'S DISEASE
A flexible drug delivery patch is described for non-invasively delivering macromolecular drugs directly to the circulatory system of a user. The patch includes multiple sealed reservoirs formed therein, the sealed reservoirs containing the macromolecular drugs which are entrapped within one of a dissolvable polymer matrix using one of nanoparticles or nanofibers or a thermo- responsive hydrogel. The macromolecular drugs being released from the sealed reservoirs and the entrapping material by activating one or more electrically addressable microheating units.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
100.
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS
Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a neurodevelop-mental disease, a myodegenerative disease, a prion disease, a lysosomal storage disease or cancer in a subject.
C07D 215/44 - Atomes d'azote liés en position 4 avec des radicaux aryle liés auxdits atomes d'azote
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07D 215/233 - Atomes d'oxygène liés en position 2 ou 4 un seul atome d'oxygène qui est lié en position 4
C07D 217/22 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle contenant l'azote
C07C 229/60 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des groupes amino et carboxyle liés en positions méta ou para
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
